Maxwell Biosciences

Maxwell Biosciences is a preclinical stage drug platform company based in Bee Cave, Texas. As a small business with one employee, Maxwell Biosciences focuses on developing innovative anti-infective solutions. The company specializes in creating a new class of patented low molecular weight drug candidates that target a wide range of pathogens, including viruses, bacteria, and fungi. Their groundbreaking CLAROMER™ brand drug discovery platform emulates the natural human immune system's antimicrobial and antiviral peptides. This platform has the potential to combat various infectious diseases, including SARS-CoV-2 (the COVID virus), Herpes virus (HSV-1), and lethal fungal infections. Maxwell Biosciences has garnered significant recognition and funding for its research. The company has secured over $35 million in non-dilutive grants and awards from governments worldwide. Their scientific breakthroughs have been validated by studies conducted at US government-funded labs and renowned institutions like Texas A&M and Baylor College of Medicine. These studies demonstrate the safety and efficacy of Maxwell's drug candidates against a range of infectious agents. For further information or to explore partnership opportunities, interested parties can visit Maxwell Biosciences' website at maxwellbiosciences.com.